AGENUS INC Research and Development in Process
AGENUS INC (AGEN) reported Research and Development in Process of $12.25 million for the 12-month period ending 2015-12-31, per its 10-K filed 2018-03-16.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentInProcess · last filed 2018-03-16
- AGENUS INC research and development in process for the quarter ending 2015-12-31 was $1.00.
- AGENUS INC research and development in process for the quarter ending 2015-09-30 was $0.00.
- AGENUS INC research and development in process for the quarter ending 2014-09-30 was $0.00.
- AGENUS INC research and development in process for fiscal 2015 was $12.25M.
| Period end | Research and Development in Process 3 month | Research and Development in Process 6 month | Research and Development in Process 9 month | Research and Development in Process 12 month |
|---|---|---|---|---|
| 2015-12-31 | $1.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16 | $1.00 derived: sum of 2 quarters · filed 2018-03-16 | $12.25M 10-K · filed 2018-03-16 | |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $12.25M 10-Q · filed 2016-11-09 | ||
| 2015-06-30 | $12.25M 10-Q · filed 2016-08-04 | |||
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-04 | $0.00 10-Q · filed 2015-11-04 | ||
| 2014-06-30 | $0.00 10-Q · filed 2015-08-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |